There are currently 414 clinical trials in Las Vegas, Nevada looking for participants to engage in research studies. Trials are conducted at various facilities, including Comprehensive Cancer Centers of Nevada, University Medical Center of Southern Nevada, Summerlin Hospital Medical Center and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study Comparing Tapinarof Cream 1% to VTAMA ® (Tapinarof Cream 1%) in the Treatment of Plaque Psoriasis
NCT06742957
Recruiting
To compare the safety and efficacy of the test (Tapinarof Cream 1%), placebo (vehicle cream) and reference VTAMA® (Tapinarof Cream 1%) treatments to demonstrate clinical equivalence in patients with plaque psoriasis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/19/2024
Locations: Site 12109, Las Vegas, Nevada
Conditions: Plaque Type Psorisis
Register for Updates
An Efficacy and Safety Study of Basimglurant (NOE-101) in Patients with Trigeminal Neuralgia.
NCT05217628
Recruiting
Trigeminal neuralgia (TN), also called "tic douloureux", is the most common form of craniofacial neuropathic pain and is considered the cause of one of the most painful afflictions known in medical practice. This study is designed to evaluate the efficacy and safety of 1.5mg - 3.5mg basimglurant in adults with TN.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
12/19/2024
Locations: Altea Research - Nevada - ClinEdge - PPDS (Site #1006), Las Vegas, Nevada
Conditions: Trigeminal Neuralgia
Register for Updates
Letrozole in Uterine Leiomyosarcoma
NCT05649956
Recruiting
This is a clinical trial to test letrozole in patients with uterine leiomyosarcoma. The main question is will treatment with letrozole extend progression-free survival in patients. Patients will receive 2/5 mg of letrozole daily.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/16/2024
Locations: Women's Cancer Center of Nevada, Las Vegas, Nevada +1 locations
Conditions: Uterine Leiomyosarcoma
Register for Updates
RE104 Clinical Lactation Study
NCT06659263
Recruiting
The purpose of this study is to obtain data necessary to characterize the elimination of RE104 and metabolites from breastmilk of health lactating volunteers to support a regulatory assessment of when mothers can safely return to breastfeeding following a single-dose of RE104 for Injection.
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
12/16/2024
Locations: PPD Inc, Las Vegas, Nevada
Conditions: Lactation
Register for Updates
A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants with IgAN, LN or C3G
NCT06419205
Recruiting
A Phase 2 Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Clinical Activity of ADX-097 Administered Subcutaneously in Male and Female Participants Aged 18 Years or Older With Immunoglobulin A Nephropathy (IgAN), Lupus Nephritis (LN), or Complement Component 3 Glomerulopathy (C3G)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/16/2024
Locations: Las Vegas, Las Vegas, Nevada
Conditions: IgA Nephropathy, Lupus Nephritis (LN), C3 (Complement Component 3) Glomerulopathy
Register for Updates
Study of Onvansertib in Combination with FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants with a KRAS or NRAS Mutation
NCT06106308
Recruiting
The purpose of this study is to assess 2 different doses of onvansertib to select the lowest dose that is maximally effective, and to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of onvansertib in combination with FOLFIRI + bevacizumab or FOLFOX + bevacizumab in patients with KRAS or NRAS-mutated metastatic colorectal cancer (CRC) in the first-line setting.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/04/2024
Locations: CCCN, Las Vegas, Nevada
Conditions: Metastatic Colorectal Cancer, CRC, KRAS/NRAS Mutation
Register for Updates
Primary and Secondary Prevention of Type 2 Diabetes Mellitus in Clark County
NCT06387797
Recruiting
This pilot and feasibility study aims to assess the effectiveness of a nutrition education intervention using the Cooking Matters for Adults Curriculum (SNAP-Ed). The study compares this standard curriculum with an enhanced version that includes the same curriculum but has additional components, incorporating specific information related to type 2 diabetes. Additionally, participants in the enhanced group will receive continuous glucose monitors to wear during the study for 10 days. The primary... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/03/2024
Locations: University of Nevada, Las Vegas, Las Vegas, Nevada
Conditions: At Risk for Type 2 Diabetes Mellitus, Pre Diabetes
Register for Updates
Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder in Pediatric Patients
NCT06690398
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled study in pediatric patients aged 5 to 17 years with a primary diagnosis of irritability associated with Autism Spectrum Disorder (ASD) based on Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition Text Revision (DSM-5-TR) and confirmed by the Kiddie Schedule for Affective Disorders and Schizophrenia Present and Lifetime Version (K-SADS-PL).
Gender:
ALL
Ages:
Between 5 years and 17 years
Trial Updated:
12/02/2024
Locations: Clinical Site, Las Vegas, Nevada
Conditions: Irritability Associated With Autism Spectrum Disorder
Register for Updates
Research Study Investigating How Well NDec Works in People With Sickle Cell Disease
NCT05405114
Recruiting
This study examines how well a new, potential medicine called NDec works and is tolerated in people with sickle cell disease. NDec is a combination of two medicines (decitabine-tetrahydrouridine). Both medicines are new for the treatment of sickle cell disease. Participants who are not taking Hydroxyurea (HU) will get NDec, NDec and placebo, or placebo. Participants who are on HU treatment before joining the study will get NDec, NDec and placebo, or continue on HU. Which treatment participants g... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/25/2024
Locations: Cure 4 the Kids Foundation, Las Vegas, Nevada
Conditions: Sickle Cell Disease
Register for Updates
A Study of EDP-938 in Non-hospitalized Adults with RSV Who Are At High Risk for Complications.
NCT05568706
Recruiting
This is a Phase 2b, randomized, double-blind, placebo-controlled study of EDP-938 administered orally for the treatment of non-hospitalized adult subjects with confirmed RSV infection who are at high risk for complications after RSV infection.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/22/2024
Locations: Clinical Research of South Nevada - Clinedge - PPDS, Las Vegas, Nevada
Conditions: RSV Infection
Register for Updates
Phase 2b Efficacy and Safety Study of Fixed Dose Drugs Combination Type of Polypill
NCT06597058
Recruiting
The goal of this clinical trial is to assess the clinical response to a drug combination type of polypill in patients with AD after 180 days of treatment. The anticipated study population are males and females aged 50-85 years with mild to severe Alzheimer's Disease. The duration of individual patient participation will be approximately 224 Days: up to 14 days for Screening, 180 days for study drug administration, and a final follow-up visit at 210 days. The planned study duration is 12-18 month... Read More
Gender:
ALL
Ages:
Between 50 years and 85 years
Trial Updated:
11/20/2024
Locations: Oasis Clinical Research (Noah Clinical Site 012), Las Vegas, Nevada
Conditions: Alzheimer Disease
Register for Updates
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
NCT04180371
Recruiting
This clinical trial is evaluating a drug called BT5528 alone and in combination with nivolumab in participants with advanced solid tumors historically known for expression of EphA2. The main goals of this study are to: * Find the recommended dose(s) of BT5528 that can be given safely to participants alone and in combination with nivolumab * Learn more about the side effects of BT5528 * Learn about how effective BT5528 is for the treatment of ovarian cancer, urothelial/bladder cancer, lung cance... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/20/2024
Locations: Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada
Conditions: Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer, Ovarian Cancer, Non-small Cell Lung Cancer, Head and Neck Cancer, Triple Negative Breast Cancer, Gastric/Upper Gastrointestinal Cancer
Register for Updates